The Quantellect read.As of Nov 19, 2026, 7 active firms cover Exagen Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $8.00 to $12.00, a moderate spread. The average target of $9.71 sits 149% above the current $3.90. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.71
+148.8% upside
Average target across 7 active firms as of Nov 19, 2026 vs $3.91 current
Highest Target$12.00
Average Target$9.71
Lowest Target$8.00
Detailed analyst forecasts for XGN
Showing 1–8 of 8 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate XGN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
XGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.19 – $-0.14 · 3 analysts · -18% YoY
Next period, 3 analysts expect Exagen Inc to earn $-0.17 a share (range $-0.19 – $-0.14), versus $-0.20 a year earlier. Full-year consensus is $-0.73, growing to $-0.50 the year after.
REVENUE · NEXT QUARTER
$18.4M
Range $17.8M – $18.9M · 3 analysts · +6% YoY
Revenue is expected to reach $18.4M (range $17.8M – $18.9M), +6.4% year-over-year. Full-year consensus is $73.7M, rising to $80.1M next year.
Top analysts covering Exagen Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XGN.
#1
KM
Kyle Mikson
Canaccord Genuity · Rank #202
Buy
$8.00+104.9% to target
Overall win rate
40%
+ Follow
#2
Mark Massaro
BTIG · Rank #220
Buy
$9.00+130.5% to target
Overall win rate
44%
+ Follow
#3
Ross Osborn
Cantor Fitzgerald · Rank #238
Buy
$10.00+156.1% to target
Overall win rate
34%
+ Follow
#4
Paul Knight
Keybanc · Rank #394
Buy
$10.00+156.1% to target
Overall win rate
39%
+ Follow
#5
AS
Anderson Schock
B. Riley Securities
Buy
$12.00+207.3% to target
Coverage
—
+ Follow
XGN stock forecast FAQ
What is XGN's average 12-month price target?+
The 7 active firms with a live target average $9.71 for Exagen Inc over the next 12 months, ranging from a $12.00 high to a $8.00 low, as of Nov 19, 2026.
Is XGN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for XGN?+
The Street-high target is $12.00 (B. Riley Securities), and the Street-low is $8.00 (Roth Capital). The average of all 7 active-firm targets is $9.71.
How many active Wall Street firms cover XGN?+
7 active firms have a recognized rating on Exagen Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering XGN?+
Among analysts who currently cover XGN, Kyle Mikson of Canaccord Genuity has the strongest overall Quantellect track record (Rank #202). Their current call is Buy with a $8.00 target.
What is Exagen Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.19 – $-0.14) across 3 analysts. Full-year EPS is projected at $-0.73, rising to $-0.50 the following year.
How much revenue is Exagen Inc expected to report next quarter?+
Consensus revenue is $18.4M (range $17.8M – $18.9M). Full-year revenue is projected at $73.7M, growing to $80.1M next year.
Have analysts been upgrading or downgrading XGN lately?+
As of Nov 19, 2026, 7 of 7 active firms rate XGN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.